FDA Approves New Patient-Facing Capabilities for Abbott's CardioMEMS HF System

The U.S. Food and Drug Administration (FDA) has approved updates to Abbott's CardioMEMS HF System, enabling patients with heart failure to view their pulmonary artery pressure (PAP) readings directly on their smartphones via the CardioGuide HF App. This development aims to provide patients with greater insight into their condition and encourage a more active role in their care. The CardioMEMS HF System uses an implanted sensor to measure PAP, which can rise as heart failure worsens, often before symptoms are noticeable.